WallStreetZenWallStreetZen

NASDAQ: KALV
Kalvista Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for KALV

Based on 2 analysts offering 12 month price targets for Kalvista Pharmaceuticals Inc.
Min Forecast
$24.00+71.06%
Avg Forecast
$29.50+110.26%
Max Forecast
$35.00+149.47%

Should I buy or sell KALV stock?

Based on 2 analysts offering ratings for Kalvista Pharmaceuticals Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their KALV stock forecasts and price targets.

KALV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-02-14
lockedlocked$00.00+00.00%2024-02-13

1 of 1

Forecast return on equity

Is KALV forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
34.53%

Forecast return on assets

Is KALV forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

KALV revenue forecast

What is KALV's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$17.8M
Avg 2 year Forecast
$29.8M
Avg 3 year Forecast
$102.7M

KALV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KALV$14.03$29.50+110.26%Buy
MREO$3.86$4.50+16.58%Strong Buy
VALN$6.80$26.00+282.35%Buy
PRAX$54.71$94.67+73.03%Buy
LRMR$11.42$17.50+53.24%Strong Buy

Kalvista Pharmaceuticals Stock Forecast FAQ

Is Kalvista Pharmaceuticals Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: KALV) stock is to Buy KALV stock.

Out of 2 analysts, 0 (0%) are recommending KALV as a Strong Buy, 2 (100%) are recommending KALV as a Buy, 0 (0%) are recommending KALV as a Hold, 0 (0%) are recommending KALV as a Sell, and 0 (0%) are recommending KALV as a Strong Sell.

If you're new to stock investing, here's how to buy Kalvista Pharmaceuticals stock.

What is KALV's revenue growth forecast for 2024-2026?

(NASDAQ: KALV) Kalvista Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.84%.

Kalvista Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast KALV's revenue for 2024 to be $616,527,369, with the lowest KALV revenue forecast at $616,527,369, and the highest KALV revenue forecast at $616,527,369. On average, 2 Wall Street analysts forecast KALV's revenue for 2025 to be $1,030,367,909, with the lowest KALV revenue forecast at $833,556,061, and the highest KALV revenue forecast at $1,227,179,757.

In 2026, KALV is forecast to generate $3,550,561,763 in revenue, with the lowest revenue forecast at $1,949,111,188 and the highest revenue forecast at $5,152,012,338.

What is KALV's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: KALV) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is KALV's Price Target?

According to 2 Wall Street analysts that have issued a 1 year KALV price target, the average KALV price target is $29.50, with the highest KALV stock price forecast at $35.00 and the lowest KALV stock price forecast at $24.00.

On average, Wall Street analysts predict that Kalvista Pharmaceuticals's share price could reach $29.50 by Feb 14, 2025. The average Kalvista Pharmaceuticals stock price prediction forecasts a potential upside of 110.26% from the current KALV share price of $14.03.

What is KALV's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: KALV) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.